198 related articles for article (PubMed ID: 24789002)
21. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
22. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
23. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
[TBL] [Abstract][Full Text] [Related]
24. Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study.
Guinard E; Bulai Livideanu C; Barthélémy H; Viguier M; Reguiai Z; Richard MA; Jullien D; Beneton N; Bara C; Vabres P; Grandvuillemin A; Marguery MC; Amelot F; Konstantinou MP; Bagheri H; Paul C;
J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1336-41. PubMed ID: 27256154
[TBL] [Abstract][Full Text] [Related]
25. Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study.
Hai BB; Anh TL; Thi Thu PN; Van HN; Van GV; Van DH
PLoS One; 2024; 19(1):e0295048. PubMed ID: 38206946
[TBL] [Abstract][Full Text] [Related]
26. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
27. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
Wallis RS
Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
[TBL] [Abstract][Full Text] [Related]
28. Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region.
Wang X; Wong SH; Wang XS; Tang W; Liu CQ; Niamul G; Wu B; Tam LS; Wu JCY; Chan FKL; Sung JJY; Ng SC
Rheumatology (Oxford); 2019 May; 58(5):803-810. PubMed ID: 30561745
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
30. [Tuberculosis among patients treated with TNF-alpha blockers].
Fuchs-Polychuck I; Avnon LS; Abu-Shakra M
Harefuah; 2007 Mar; 146(3):212-8, 245. PubMed ID: 17460930
[TBL] [Abstract][Full Text] [Related]
31. Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report.
Skroza N; Proietti I; Bernardini N; La Viola G; Nicolucci F; Tolino E; Zuber S; Potenza C
Cutis; 2012 Sep; 90(3):120-2. PubMed ID: 23094309
[TBL] [Abstract][Full Text] [Related]
32. [Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease].
Jin BC; Moon HJ; Kim SW
Korean J Gastroenterol; 2022 Aug; 80(2):72-76. PubMed ID: 36004634
[TBL] [Abstract][Full Text] [Related]
33. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.
Banerjee R; Ali RAR; Wei SC; Adsul S
Gut Liver; 2020 Nov; 14(6):685-698. PubMed ID: 33191310
[TBL] [Abstract][Full Text] [Related]
34. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
35. The risk of tuberculosis in patients treated with TNF antagonists.
Salgado E; Gómez-Reino JJ
Expert Rev Clin Immunol; 2011 May; 7(3):329-40. PubMed ID: 21595599
[TBL] [Abstract][Full Text] [Related]
36. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.
Nogueira M; Warren RB; Torres T
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):824-834. PubMed ID: 32790003
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
[TBL] [Abstract][Full Text] [Related]
38. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy.
Mastorino L; Dapavo P; Trunfio M; Avallone G; Rubatto M; Calcagno A; Ribero S; Quaglino P
Acta Derm Venereol; 2022 Nov; 102():adv00821. PubMed ID: 36065745
[TBL] [Abstract][Full Text] [Related]
39. [Diagnostics of latent tuberculosis (TB) in adult vaccinated patients (BCG) in Croatia before introduction of tumor necrosis factor antagonist therapy].
Popović-Grle S; Babić-Naglić D
Reumatizam; 2008; 55(1):31-5. PubMed ID: 19024268
[TBL] [Abstract][Full Text] [Related]
40. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
Sato S; Nagai H
Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
